抗肾小球基底膜病治疗标准
本文综述抗肾小球基底膜(anti-GBM)病的当前治疗标准,并讨论其病理生理、诊断、预后预测和管理的新进展。抗GBM病由针对IV型胶原α3链的自身抗体引起,约50%病例出现快速进展性肾小球肾炎伴肺出血。传统三联治疗(血浆置换联合环磷酰胺和糖皮质激素)显著改善预后,尤其对就诊时非透析依赖患者;透析依赖患者肾脏恢复可能性较低,治疗决策需考虑活检发现、临床严重程度和标准免疫抑制的潜在禁忌。
要点
- 抗GBM病由抗IV型胶原α3链自身抗体引起,约50%病例伴肺出血。
- 血浆置换联合环磷酰胺和糖皮质激素显著改善预后,尤其非透析依赖患者。
- 经典抗GBM病复发罕见,长期维持免疫抑制非常规需要;双阳性患者复发风险较高,需维持免疫抑制治疗。
核心结论
- 抗GBM病的标准治疗为血浆置换联合环磷酰胺和糖皮质激素,显著改善预后,尤其对就诊时非透析依赖患者。
- 透析依赖患者肾脏恢复可能性较低,治疗决策需考虑活检发现、临床严重程度和标准免疫抑制的潜在禁忌。
- 经典抗GBM病复发罕见,长期维持免疫抑制非常规需要;双阳性患者复发风险较高,需维持免疫抑制治疗。
- 非典型抗GBM表现(包括血清阴性病例)已被更好认识,但最佳管理仍不明确。
研究设计与样本
- 本文为综述,回顾抗GBM病的当前治疗标准并讨论病理生理、诊断、预后预测和管理的新进展。
主要发现
- 抗GBM病由针对IV型胶原α3链的自身抗体引起,导致快速进展性肾小球肾炎,约50%病例伴肺出血。
- 诊断依赖临床特征、肾活检显示沿GBM线性IgG沉积和/或检测循环抗GBM抗体。
- 历史上未治疗疾病快速致命,引入血浆置换联合环磷酰胺和糖皮质激素后预后显著改善,尤其就诊时非透析依赖患者。
- 透析依赖患者肾脏恢复可能性较低。
- 与ANCA相关血管炎不同,经典抗GBM病复发罕见,长期维持免疫抑制非常规需要;双阳性患者复发风险较高,需维持免疫抑制治疗。
关键数值与推荐
- 诊断依赖临床特征、肾活检显示沿GBM线性IgG沉积和/或检测循环抗GBM抗体。
- 约50%病例出现肺出血。
临床怎么用
- 透析依赖患者的治疗决策需考虑活检发现、临床严重程度和标准免疫抑制的潜在禁忌。
- 双阳性患者需维持免疫抑制治疗。
局限性
- 非典型抗GBM表现(包括血清阴性病例)的最佳管理仍不明确。
- 未来研究应明确口服与静脉环磷酰胺在抗GBM病中的使用、澄清利妥昔单抗的作用并确定imlifidase等新兴疗法的地位。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We review the current standards of treatment and discuss novel developments in the pathophysiology, diagnosis, outcome prediction and management of anti-glomerular basement membrane (anti-GBM) disease. Anti-GBM disease is a unique form of small vessel vasculitis affecting the glomerular and pulmonary capillaries. It is caused by autoantibodies directed against the α3 chain of type IV collagen, leading to rapidly progressive glomerulonephritis with pulmonary haemorrhage in ∼50% of cases. Diagnosis relies on clinical features, kidney biopsy showing linear IgG deposition along the GBM, and/or detection of circulating anti-GBM antibodies. Historically, untreated disease was rapidly fatal, but the introduction of plasma exchange combined with cyclophosphamide and glucocorticoids has significantly improved outcomes, particularly in patients who are not dialysis-dependent at presentation. Dialysis-dependent patients have a lower likelihood of renal recovery, and treatment decisions must consider biopsy findings, clinical severity and potential contraindications to standard immunosuppression. Unlike anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis, relapses are rare in classic anti-GBM disease, and long-term maintenance immunosuppression is not routinely required. However, 'double positive' patients (anti-GBM and ANCA) have a higher relapse risk and require maintenance immunosuppressive treatment. Atypical anti-GBM presentations, including seronegative cases, are now better recognized but their optimal management remains unclear. Future research should define the use of oral versus intravenous cyclophosphamide in anti-GBM disease, clarify the role of rituximab and determine the place of emerging therapies such as imlifidase. Advances in risk stratification and ongoing trials are expected to inform treatment individualization and to improve treatment approaches for this aggressive autoimmune disease.
引用
- McAdoo SP, Pusey CD. Anti-glomerular basement membrane disease-treatment standard. Nephrol Dial Transplant. 2025. PMID: 40973182. doi:10.1093/ndt/gfaf190
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。